British MedTech company TestCard has appointed a new chief executive officer to manage its next phase of growth as it adopts a rapid expansion programme.
TestCard is a cutting-edge British digital diagnostics company that is revolutionising healthcare by increasing the accessibility and diagnostic capability of non-invasive testing.
With technology that can turn a smartphone into a clinical grade scanner, TestCard launched its first commercial product, a urinary tract infection (UTI) self-test at the end of 2020 which is sold through its UK pharmacy partners.
TestCard went on to launch ClearScreen – a digital reading, recording, and reporting solution for medical tests developed in collaboration with Guy’s and St Thomas’ NHS Foundation Trust and SureScreen Diagnostics Ltd in July 2021.
The solution comprises a mobile app which provides rapid reading and recording of test results at the point of care whilst significantly reducing admin time for hospital staff and improving traceability.
The scanned test result can be shared into a patient’s electronic record in seconds. It is hoped that the ClearScreen app, which has been validated by Guy’s and St Thomas’ NHS Foundation Trust, could now be rolled out across other NHS Trusts in England.
Elmer Monster has over 20 years of experience across the healthcare industry. He held various senior leadership roles in commercial, finance and strategy at Roche across both the pharmaceuticals and diagnostics divisions.
Monster was recently CFO of Swiss MedTech company Coretag, which focused on the development of cancer imaging and targeted radiotherapy. Elmer has been a commercial advisor to TestCard for several years and was appointed to TestCard’s board earlier this year.
He takes over as CEO from Chris Craig-Wood, who remains a substantial shareholder going forward.
“I’m very pleased to be handing the leadership baton to Elmer as we enter such an exciting phase in the company’s growth,” said Craig-Wood.
“We always planned to transition to a new leader for the next chapter with the requisite deep domain knowledge to build on the solid foundations that are now in place, particularly following the recent signing of our landmark contract with Roche.”
TestCard raised in excess of $10 million in its latest round of fundraising earlier this year and recently signed a collaboration contract with Roche that will see its ClearScreen app included on Roche’s newest point-of-care solution – the cobas® pulse system.
TestCard is also supporting Yorkshire Cancer Research in a pioneering screening trial to provide its diagnostic technology and test kits to allow 6,000 people to test for bladder health problems such as bladder cancer from the comfort of their home.
Monster said: “It’s a great honour to become chief executive of such an innovative company. TestCard is bringing testing into the digital age, empowering people to test at the point of care, both at home and in clinical settings and enabling access to improved patient outcomes.”
MedTech 50 – UK’s most innovative medical technology creators for 2022